Current Status of Intravenous Thrombolysis for Acute Ischemic Stroke in Asia

No abstract is available for this paper.

• Publication year

  2011

• Venue

  International Journal of Stroke

• Publication date

  2011-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1747-4949.2011.00671.xPMID 22111797
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• OpenEpi: Open Source Epidemiologic Statistics for Public Health. Version 2.3.1.

  2013cited by this paper
• Outcomes of intravenous thrombolytic therapy for acute ischemic stroke with an integrated acute stroke referral network: initial experience of a community-based hospital in a developing country.

  2012cited by this paper
• Efficacy and safety of different doses of intravenous tissue plasminogen activator in Chinese patients with ischemic stroke.

  2010cited by this paper
• Predictors of major neurological improvement after intravenous thrombolysis in acute ischemic stroke: a hospital-based study from south India.

  2010cited by this paper
• Utilization and outcome of thrombolytic therapy for acute stroke in Pakistan

  2010cited by this paper
• Patients with thrombolysed stroke in Vietnam have an excellent outcome: results from the Vietnam Thrombolysis Registry

  2010cited by this paper
• Effects of 0.6 mg/kg Intravenous Alteplase on Vascular and Clinical Outcomes in Middle Cerebral Artery Occlusion: Japan Alteplase Clinical Trial II (J-ACT II)

  2010cited by this paper
• Feasibility and safety of intravenous thrombolysis in multiethnic Asian stroke patients in Singapore.

  2010cited by this paper
• An expedited stroke triage pathway: the key to shortening the door-to-needle time in delivery of thrombolysis.

  2010cited by this paper
• Thrombolysis With 0.6 mg/kg Intravenous Alteplase for Acute Ischemic Stroke in Routine Clinical Practice: The Japan post-Marketing Alteplase Registration Study (J-MARS)

  2010cited by this paper
• Outcomes of Thrombolytic Therapy for Acute Ischemic Stroke in Chinese Patients: The Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) Study

  2010cited by this paper
• Routine Use of Intravenous Low-Dose Recombinant Tissue Plasminogen Activator in Japanese Patients: General Outcomes and Prognostic Factors From the SAMURAI Register

  2009cited by this paper
• Intravenous thrombolytic therapy for acute ischemic stroke: the experience of a community hospital.

  2009cited by this paper
• Hospital resources for urokinase/recombinant tissue-type plasminogen activator therapy for acute stroke in Beijing.

  2009cited by this paper
• Intravenous thrombolysis for acute ischemic stroke: the Malabar experience 2003 to 2008.

  2009cited by this paper
• Hyperacute thrombolysis with recombinant tissue plasminogen activator of acute ischemic stroke: Feasibility and effectivity from an Indian perspective

  2008cited by this paper
• Stroke.

  2008cited by this paper
• Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study.

  2007cited by this paper
• Post-licensed 1-year experience of systemic thrombolysis with tissue plasminogen activator for ischemic stroke in a Japanese neuro-unit.

  2007cited by this paper
• Hyperacute thrombolysis with IV rtPA of acute ischemic stroke: efficacy and safety profile of 54 patients at a tertiary referral center in a developing country.

  2007cited by this paper
• Alteplase at 0.6 mg/kg for Acute Ischemic Stroke Within 3 Hours of Onset: Japan Alteplase Clinical Trial (J-ACT)

  2006cited by this paper
• Eligibility for Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke

  2006cited by this paper
• Thrombolytic therapy in acute ischemic stroke in Asia: The first prospective evaluation.

  2006cited by this paper
• Acute Stroke Care in the US: Results from 4 Pilot Prototypes of the Paul Coverdell National Acute Stroke Registry

  2005cited by this paper
• Is Intravenous Thrombolysis Feasible in a Developing Country?

  2005cited by this paper
• tPA use for Stroke in the Registry of the Canadian Stroke Network

  2005cited by this paper
• The global stroke initiative.

  2004cited by this paper
• Measuring inconsistency in meta-analyses

  2003cited by this paper
• Frequency of Thrombolytic Therapy in Patients With Acute Ischemic Stroke and the Risk of In-Hospital Mortality: The German Stroke Registers Study Group

  2003cited by this paper
• Quantifying heterogeneity in a meta‐analysis

  2002cited by this paper
• The Differences in Thrombolytic Effects of Administrated Recombinant t-PA between Japanese and Caucasians

  2002cited by this paper
• Improving the Quality of Reports of Meta-Analyses of Randomised Controlled Trials: The QUOROM Statement

  1999cited by this paper
• Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses.

  1999cited by this paper
• Stroke in the developing world.

  1998cited by this paper
• Intracranial stenosis in Chinese patients with acute stroke

  1998cited by this paper
• Mortality by cause for eight regions of the world: Global Burden of Disease Study

  1997cited by this paper
• Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction. The Northern Manhattan Stroke Study.

  1995cited by this paper
• Clinical Efficacy and Safety of Intravenous Tissue Plasminogen Activator in Acute Embolic Stroke: A Randomized, Double-Blind, Dose-Comparison Study of Duteplase

  1995cited by this paper
• Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.

  1995cited by this paper
• Tissue plasminogen activator for acute ischemic stroke.

  1995cited by this paper
• Spectacular shrinking deficit : rapid recovery from a major hemispheric syndrome by migration of an embolus

  1993cited by this paper
• Classification of Subtype of Acute Ischemic Stroke: Definitions for Use in a Multicenter Clinical Trial

  1993cited by this paper
• Intravenous Tissue Plasminogen Activator Ameliorates the Outcome of Hyperacute Embolic Stroke

  1993cited by this paper
• 'Spectacular shrinking deficit'

  1992cited by this paper
• Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke

  1992cited by this paper
• Chinese‐white differences in the distribution of occlusive cerebrovascular disease

  1990cited by this paper
• Racial differences in the distribution of anterior circulation occlusive disease

  1984cited by this paper
• Racial differences in cerebrovascular disease. Angiographic evaluation of Japanese and American populations.

  1967cited by this paper

• One‐Year Outcomes After Intravenous Recombinant Tissue Plasminogen Activator for Ischemic Stroke: A Real‐World Study

  2025influential citation
• Comparison of Effectiveness and Safety of Low-Dose Versus Standard-Dose Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke: A Meta-Analysis

  2023influential citation
• Time-to-care metrics in patients with interhospital transfer for mechanical thrombectomy in north-east Germany: Primary telestroke centers in rural areas vs. primary stroke centers in a metropolitan area

  2023cites this paper
• Current status of acute ischemic stroke management in Iran: Findings from a single-center study

  2022cites this paper
• Cost-Effectiveness of Low-Dose Compared to Standard-Dose Alteplase for Acute Ischemic Stroke in China: A Within-Trial Economic Evaluation of the ENCHANTED Study

  2022cites this paper
• The Association between Serum Anion Gap and All-Cause Mortality in Cerebral Infarction Patients after Treatment with rtPA: A Retrospective Analysis

  2022cites this paper
• Intravenous thrombolysis with alteplase in the treatment of acute cerebral infarction

  2022cites this paper
• Endovascular treatment for ischemic stroke patients with and without atrial fibrillation, and the effects of adjunctive pharmacotherapy: a narrative review

  2022cites this paper
• Stroke patients from rural areas have lower chances for long-term good clinical outcome after mechanical thrombectomy.

  2021cites this paper
• Disparities between Asian and Non-Asian Thrombolyzed Acute Ischemic Stroke Patients in the Enhanced Control of Hypertension and Thrombolysis Stroke Trial

  2021cites this paper
• Predictive value of coagulation factor XIII on bleeding risk in ischemic stroke patients treated with intravenous thrombolysis.

  2021cites this paper
• Impact of estimated-weight-base dose of alteplase in acute stroke treatment on clinical outcome.

  2021cites this paper
• European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke

  2021cites this paper
• Acute ischemic stroke: improving access to intravenous tissue plasminogen activator

  2020cites this paper
• Comparative study of intravenous thrombolysis with rt-PA and urokinase for patients with acute cerebral infarction

  2020cites this paper
• Effect of multi-level stroke education on treatment and prognosis of acute ischemic stroke.

  2020cites this paper
• Magnetic Resonance Imaging–Guided Thrombolysis (0.6 mg/kg) Was Beneficial for Unknown Onset Stroke Above a Certain Core Size

  2020cites this paper
• Utilization and outcomes with low dose tissue plasminogen activator as intravenous thrombolytic therapy for ischaemic stroke at Aga Khan University Hospital, Karachi: a retrospective analysis.

  2019cites this paper
• Treatment Delays for Patients With Acute Ischemic Stroke in an Iranian Emergency Department: A Retrospective Chart Review

  2019cites this paper
• The National Institute for Health Research Hyperacute Stroke Research Centres and the ENCHANTED trial: the impact of enhanced research infrastructure on trial metrics and patient outcomes

  2019cites this paper
• The risk of conclusion change in systematic review updates can be estimated by learning from a database of published examples.

  2019cites this paper
• Management of Acute Ischemic Stroke

  2019cites this paper
• Applicability of ENCHANTED trial results to current acute ischemic stroke patients eligible for intravenous thrombolysis in England and Wales: Comparison with the Sentinel Stroke National Audit Programme registry

  2019cites this paper
• Low-dose versus standard-dose alteplase in acute ischemic stroke in Asian stroke registries: an individual patient data pooling study

  2019cites this paper
• Renal Dysfunction Associated with Symptomatic Intracranial Hemorrhage after Intravenous Thrombolysis.

  2019cites this paper
• Interaction of Blood Pressure Lowering and Alteplase Dose in Acute Ischemic Stroke: Results of the Enhanced Control of Hypertension and Thrombolysis Stroke Study

  2019cites this paper
• Hémorragie intracrânienne et pronostic fonctionnel post-AVC chez les patients traités par thrombolyse et thrombectomie : influence des antiagrégants plaquettaires

  2018cites this paper
• Lipid-Lowering Pretreatment and Outcome Following Intravenous Thrombolysis for Acute Ischaemic Stroke: A Post Hoc Analysis of the Enhanced Control of Hypertension and Thrombolysis Stroke Study Trial

  2018cites this paper
• Lipid-lowering pretreatment and outcome following intravenous thrombolysis for acute ischaemic stroke: a post-hoc analysis of the ENCHANTED trial

  2018cites this paper
• Current status of intravenous tissue plasminogen activator dosage for acute ischaemic stroke: an updated systematic review

  2018cites this paper
• Stroke thrombolysis in the Philippines

  2018cites this paper
• OBSOLETE: Cerebrovascular Disease

  2017cites this paper
• Low-Dose vs Standard-Dose Alteplase for Patients With Acute Ischemic Stroke: Secondary Analysis of the ENCHANTED Randomized Clinical Trial

  2017cites this paper
• Influence of Renal Impairment on Outcome for Thrombolysis-Treated Acute Ischemic Stroke: ENCHANTED (Enhanced Control of Hypertension and Thrombolysis Stroke Study) Post Hoc Analysis

  2017cites this paper
• Characteristics, management and response to alteplase in China versus non-China participants of the ENCHANTED trial

  2017cites this paper
• Prognostic Parameters for Symptomatic Intracranial Hemorrhage after Intravenous Thrombolysis in Acute Ischemic Stroke in an Asian Population.

  2017cites this paper
• Influence of Renal Impairment on Outcome for Thrombolysis-Treated Acute Ischemic Stroke

  2017cites this paper
• The need for a population-based, dose optimization study for recombinant tissue plasminogen activator in acute ischemic stroke: A study from a tertiary care teaching hospital from South India

  2017cites this paper
• The Impact of Discrepancy between Measured versus Stated Weight on Hemorrhagic Transformation and Clinical Outcomes after Intravenous Alteplase Thrombolysis

  2017cites this paper
• Low- Versus Standard-Dose Alteplase in Patients on Prior Antiplatelet Therapy: The ENCHANTED Trial (Enhanced Control of Hypertension and Thrombolysis Stroke Study)

  2017cites this paper
• Thrombolysis for Acute Ischemic Stroke: Experience in Dubai, and Comparison of Arab with Non-Arab Population

  2016cites this paper
• Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke.

  2016cites this paper
• Hyperdense Artery Sign, Clot Characteristics, and Response to Intravenous Thrombolysis in Han Chinese People with Acute Large Arterial Infarction.

  2016cites this paper
• Statistical analysis plan for evaluating low‐ vs. standard‐dose alteplase in the ENhanced Control of Hypertension and Thrombolysis strokE stuDy (ENCHANTED)

  2015cites this paper
• Gaps and hurdles deter against following stroke guidelines for thrombolytic therapy in Iran: exploring the problem.

  2015cites this paper
• Rationale, Design, and Progress of the ENhanced Control of Hypertension ANd Thrombolysis Stroke Study (ENCHANTED) Trial: An International Multicenter 2 × 2 Quasi-Factorial Randomized Controlled Trial of Low- vs. Standard-Dose rt-PA and Early Intensive vs. Guideline-Recommended Blood Pressure Lowerin

  2015cites this paper
• Standard-Dose Intravenous Tissue-Type Plasminogen Activator for Stroke Is Better Than Low Doses

  2014cites this paper
• Response to letter regarding article, "standard-dose intravenous tissue-type plasminogen activator for stroke is better than low doses".

  2014cites this paper
• The Role of National Guidelines While Staying Abroad with an Acute Stroke

  2014cites this paper
• Editorial Current Status and Future of Acute Stroke Thrombolysis with Tissue Plasminogen Activator

  2014cites this paper
• Different Doses of Recombinant Tissue-Type Plasminogen Activator for Acute Stroke in Chinese Patients

  2014cites this paper
• “Standard-Dose Intravenous Tissue-Type Plasminogen Activator for Stroke Is Better

  2014cites this paper
• The impact factors on the cost and length of stay among acute ischemic stroke.

  2013cites this paper
• Postthrombolysis Outcomes in Acute Ischemic Stroke Patients of Asian Race-Ethnicity

  2013cites this paper
• National survey of thrombolytic therapy for acute ischemic stroke in Taiwan 2003-2010.

  2013cites this paper
• Timing of recanalization after intravenous thrombolysis and functional outcomes after acute ischemic stroke.

  2013cites this paper
• Comparison of Risk-scoring Systems in Predicting Symptomatic Intracerebral Hemorrhage After Intravenous Thrombolysis

  2013cites this paper
• Safety and efficacy of 0.6 mg/kg rt‐PA: optimum rt‐PA dose revisited

  2012cites this paper
• 한국 뇌졸중 진료지침 급성기 치료 중 혈전용해술에 대한 내용의 부분개정

  2012cites this paper
• More on: optimal dose for stroke thrombolysis in Asians

  2012cites this paper
• Focused Update of Korean Clinical Practice Guidelines for the Thrombolysis in Acute Stroke Management

  2012cites this paper
• More on: optimal dose for stroke thrombolysis in Asians

  2012cites this paper
• Stroke Systems of Care and Impact on Acute Stroke Treatment

  year unknowncites this paper